A study that revealed that hnRNP K over expression may cause B-cell lymphomas; therefore the most common types of blood cancer. Because The finding that this tumour suppressor gene may also cause cancer may lead to new methods for assessing patients and to the development of novel therapeutic approaches.

Tumour suppressor gene

The findings of the study, led by Sean Post; associate professor of Leukaemia at MD Anderson; are publish in the Journal of the National Cancer Institute (JNCI). Besides CNIO; the University Hospital 12 de Octubre and Complutense University of Madrid also participated in the study.

B lymphocytes are a type of white blood cells that develop in the bone marrow. They produce antibodies used by the immune system to neutralise pathogenic microorganisms. therefore The different types of lymphomas affecting these types of blood cells are the most frequent blood cancers. Their prognosis and treatments depend on the cancer type and stage, since B-cell lymphomas may be slow-growing (malignant) ;or fast-growing (highly malignant).

Types of lymphomas affecting

Miguel Gallardo is the scientist who characterised hnRNP K as a tumour suppressor gene. His findings are publish in Cancer Cell when he is a postdoctoral fellow at MD Anderson. It is already know that hnRNP K regulates a multitude of cellular processes; and that both its over expression and under expression are involve in disease development.

Elevated expression of hnRNP K had also been observe in patients with high-grade solid tumours. The tumour-promoting function of hnRNP K is confirm for B-cell lymphomas in the study publish in JNCI. Gallardo is co-first author alongside Prerna Malaney; postdoctoral fellow at MD Anderson.

High-grade solid tumours

“Over expression of hnRNP K is often associated with poor recovery and low survival rates;” says Gallardo. “This was confirmed by findings that over expression of hnRNP K in transgenic mice resulted in development of lymphoma and reduced survival.”The study team found that the oncogenic potential of hnRNP K stems from its ability to regulate a common oncogene called MYC; which is often linked to blood cancer.

The study results indicated that hnRNP K is an oncogene when overexpress and represents a novel mechanism for c-MYC activation that is different from those observed in other tumour types thus far. Lymphoma patients might benefit from more personalised therapies based on targeting hnRNP K or c-MYC.

In this regard, the H12O-CNIO Haematological Malignancies Clinical Research Unit is actively collaborating with other researchers at CNIO working on the development of new hnRNP K modulators for future clinical use. These researchers are Inés Muñoz, Ramón Campos-Olivas and Sonia Martínez, from the Crystallography and Protein Engineering Unit; the Spectroscopy and NMR Unit, and the Medical Chemistry Section, respectively.